Insulin secretagogues

Oral hypoglycaemic agents Oral blood glucoselowering drugs Insulin secretagogues Antihypergly-caemics... 

SLTR1/Kir6.2 Glibenclamide and glipizide that block pancreatic KAXP channels have been used for the treatment of type II diabetes. New class of insulin secretagogues includes repaglinide and nateglinide, which improve insulin secretion, action and reduce carbohydrate absorption. 

Insulin Desensitization Insulin Receptor Insulin Resistance Insulin Secretagogues Insulin-like Growth Factor Integrase Integrin, a 4(31 Integrin, a 4(3 7 Integrin, a IIb(3 3... 

Insulin secretagogue A substance or medication that stimulates insulin secretion from the pancreas. 

Glimepiride (Y) Amaryl Short-acting insulin secretagogues 1,2,4 1-2 0.5-1 2 8 24 hours Metabolized in liver to inactive metabolites... 

Near-normal-weight patients may be treated with insulin secretagogues. 

Failure of initial therapy should result in addition of another class of drug. Substitution of a drug from another class should be reserved for drug intolerance. Metformin and an insulin secretagogue are often first- and second-line therapy. 

In rats, infusion of the insulin secretagogues arginine and glucose induced a calciuria proportional to serum insulin levels. Suppression of insulin secretion by mannoheptulose or streptozotocin prevented the calciuria. Parathyroidectomy did not affect arginine-induced hypercalciuria in the rat, so insulin is not inhibiting parathyroid hormone secretion or activity. 

Do not switch patients whose hyperglycemia is not adequately controlled with glyburide or other insulin secretagogues to nateglinide do not add nateglinide to their treatment regimen. 

Nateglinide, a D-phenylalanine derivative, is the latest insulin secretagogue to become clinically available. Nateglinide stimulates very rapid and... 

Exenatide is approved for use in individuals who fail to achieve desired glycemic control on biguanides, or biguanides plus sulfonylureas. Hypoglycemia is a risk when exenatide is used with an insulin secretagogue or with insulin. The doses of the latter drugs have to be reduced at the initiation of exenatide therapy and subsequently titrated. 

Insulin secretagogues (sulfonylureas, meglitinides, or D -phenylalanine derivatives), Tzds, biguanides, -glucosidase inhibitors, and incretin-based agents are not approved for use in type 1 diabetes. 

Cohen RM, Ramlo-Halsted BA. How do the new insulin secretagogues compare Diabetes Care 2002 25(8) 1472-3. 

Carroll MF, Izard A, Riboni K, Burge MR, Schade DS. Control of postprandial hyperglycemia optimal use of short-acting insulin secretagogues. Diabetes Care 2002 25(12) 2147-52. 

Schmitz O, Lund S, Andersen PH, Jonler M, Porksen N. Optimizing insulin secretagogue therapy in patients with... 

Dailey G. Insulin secretagogues who, what, when, and how Curr Diab Rep. 2005 5 329-332. 

---